Post hoc analyses of the phase 2 NOBILITY trial reveal that adding obinutuzumab to standard lupus nephritis therapy enhances kidney preservation and reduces glucocorticoid reliance.
Researchers compared rates of in-hospital mortality among patients with and without systemic lupus erythematosus to determine the trends and risk factors associated with death related to SLE.
After the agent did not have a significant effect on the primary end point in a previous phase 3 trial, researchers used a secondary end point from that trial as the primary end point of a new phase 3...
In a new study, researchers compared the individual safety and efficacy of cyclosporine, mycophenolate mofetil, and azathioprine as long-term maintenance therapies among individuals with lupus nephritis. ...
While hydroxychloroquine is a common medication in the management of systemic lupus erythematosus, adherence to it is poor. Researchers analyzed data on more than 1900 participants to determine how...
Researchers evaluated data on more than 2000 individuals with systemic lupus erythematosus to determine whether a DMARD is associated with increased survival.
The authors of a new study evaluated the prevalence and outcomes of 19 neuropsychiatric events in a cohort of patients with systemic lupus erythematosus.
